Blackhawk Growth Corp, a leading investment holding company, is making significant strides in advancing human clinical trials within the field of asthma AI technology. The company recently provided an update on its Hardenbrook portfolio company, Asthmatic AI, which is focused on developing asthma attack prediction technology for clinical management.
Asthmatic AI, in collaboration with Life AI Corp, has successfully completed human clinical trials with 50 participants and is now moving forward with the next phase involving 250 participants. The technology utilizes wearable devices and a mobile application to collect data and assess the risk of an asthma attack occurring, allowing for timely intervention. By analyzing various biophysical information and environmental data, Asthmatic AI aims to predict asthma attacks and prevent them from happening.
With asthma-related deaths reaching alarming rates globally, Asthmatic AI’s innovative approach offers a promising solution to manage this serious health condition. The technology leverages artificial intelligence models to predict asthma attacks, ultimately reducing the burden on individuals and healthcare systems.
Hardenbrook Group, in partnership with world-class research organizations, is committed to identifying and investing in valuable intellectual property, such as health tech AI companies like Asthmatic AI. The company is also merging its portfolio of AI-focused companies, including Mood AI and Autism AI, with plans to launch several health tech AI projects in the near future.
Blackhawk Growth Corp’s CEO, Justin Hanka, and Chairman, Anoosh Manzoori, are dedicated to exploring scalable technology opportunities, particularly in the fields of AI, health, and environmental technology. As Blackhawk continues to drive innovation and growth in the health tech sector, the company’s focus on developing cutting-edge solutions remains unwavering.
In conclusion, Blackhawk Growth Corp’s commitment to advancing asthma AI technology through human clinical trials demonstrates its dedication to making a positive impact in the healthcare industry. With promising developments on the horizon, the company is well-positioned to lead the way in revolutionizing the management of asthma through innovative technological solutions.
